Immix Biopharma, Inc. (IMMX) Financials

The upward trajectory in R&D spending suggests that the company is entering a more resource-intensive phase of its clinical development cycle. Investors should monitor whether this increased spending correlates with accelerated patient enrollment, as the current lack of revenue makes the company entirely dependent on its existing cash reserves to fund these operational outlays.

The lack of operating leverage is expected for a clinical-stage firm, but the consistent increase in SG&A alongside R&D suggests a growing administrative burden. This trend warrants further investigation into whether management can maintain cost discipline as they transition toward more complex, late-stage clinical trials.